Parliamentary questions

1434. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the frequency of identified human-data-entry errors across major clinical and administrative systems; and if so, the annual figures recorded since 2020. [39811/26]

1435. Deputy Ken O'Flynn asked the Minister for Health whether any HSE systems trigger automatic escalation procedures when data quality issues exceed predefined thresholds; and if she will provide details. [39812/26]

1436. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains a national register of serious data-quality incidents affecting patient care, referrals, waiting lists, prescribing, diagnostics or scheduling systems. [39813/26]

1437. Deputy Ken O'Flynn asked the Minister for Health the number of incidents since 2020 in which inaccurate or incomplete data entry contributed to delayed treatment, incorrect referrals, patient-safety incidents or financial overpayments. [39814/26]

1438. Deputy Ken O'Flynn asked the Minister for Health whether any independent audit has assessed the cumulative national risk posed by fragmented or inconsistent data-quality controls across HSE systems. [39815/26]

1439. Deputy Ken O'Flynn asked the Minister for Health whether regional HSE bodies operate under uniform national data-quality standards and escalation mechanisms; and if she will provide details of any regional variation. [39816/26]

1440. Deputy Ken O'Flynn asked the Minister for Health who holds ultimate accountability within the HSE for national data-quality assurance and human-error mitigation across clinical and operational systems. [39817/26]

1441. Deputy Ken O'Flynn asked the Minister for Health whether any internal risk assessment, service review, or operational assessment identified the absence of SCAN nurses in the HSE Mid-West as a deficiency, unmet service need, or patient-safety concern at any time since 2020. [39818/26]

1442. Deputy Ken O'Flynn asked the Minister for Health when the HSE first identified the need for dedicated SCAN nurses in the HSE Mid-West region. [39819/26]

1443. Deputy Ken O'Flynn asked the Minister for Health whether the HSE conducted any benchmarking comparing SCAN coverage across HSE regions prior to approving funding for two SCAN nurses in the Mid-West. [39820/26]

1444. Deputy Ken O'Flynn asked the Minister for Health whether any adverse incident reviews, crisis response reviews, or emergency department escalation reviews referenced the absence of SCAN services in the Mid-West. [39821/26]

1445. Deputy Ken O'Flynn asked the Minister for Health how many dedicated SCAN nurses are currently operating in each HSE region. [39822/26]

1446. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has established recommended staffing ratios or population benchmarks for SCAN services nationally. [39823/26]

1447. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE considers the provision of only two SCAN nurses sufficient for the Mid West population and crisis demand profile. [39824/26]

1448. Deputy Ken O'Flynn asked the Minister for Health when the two approved SCAN nurse posts for the Mid-West are expected to become operational. [39825/26]

1449. Deputy Ken O'Flynn asked the Minister for Health whether the posts have been advertised, filled, or remain vacant. [39826/26]

1450. Deputy Ken O'Flynn asked the Minister for Health whether any business case or service development proposal supporting the Mid-West SCAN expansion will be published. [39827/26]

1451. Deputy Ken O'Flynn asked the Minister for Health whether the HSE formally reviewed reimbursement, managed access, or pricing decisions relating to omaveloxolone (skyclarys) in France, Germany, Italy, Spain, Belgium, the Netherlands or the United Kingdom as part of the Irish reimbursement assessment process; and if she will provide details of any such comparative analysis undertaken. [39831/2…

1452. Deputy Ken O'Flynn asked the Minister for Health whether the National Centre for Pharmacoeconomics considered any international managed access agreements, risk-sharing agreements, conditional reimbursement models or outcomes-based reimbursement arrangements in respect of omaveloxolone (Skyclarys); and if she will provide details of the jurisdictions and models reviewed. [39832/26]

1453. Deputy Ken O'Flynn asked the Minister for Health whether any orphan-drug specific weighting, modified cost-effectiveness threshold, severity adjustment or rare disease reimbursement framework was applied in the assessment of omaveloxolone (skyclarys); and if she will make a statement on the matter. [39833/26]

1454. Deputy Ken O'Flynn asked the Minister for Health whether the assessment of omaveloxolone (skyclarys) included analysis of indirect societal costs associated with Friedreich's ataxia, including disability supports, caregiver burden, loss of educational participation, workforce impacts and long-term health service utilisation; and if she will provide details of the methodology used. [39834/26]

1455. Deputy Ken O'Flynn asked the Minister for Health whether Ireland currently operates a distinct reimbursement or pharmacoeconomic assessment pathway for orphan medicines or ultra-rare disease therapies; if so, to provide details of the framework and criteria applied; and if she will make a statement on the matter. [39835/26]

1456. Deputy Ken O'Flynn asked the Minister for Health the number of orphan or ultra-rare disease medicines which received a negative reimbursement recommendation from the National Centre for Pharmacoeconomics in each year since 2020; and the number subsequently approved for reimbursement following commercial negotiation or further review. [39836/26]

1457. Deputy Ken O'Flynn asked the Minister for Health the average period between European Medicines Agency authorisation and final reimbursement decision in Ireland for orphan medicines in each year since 2020; and how this compares with the EU average where such data is available. [39837/26]

1458. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any comparative analysis of Ireland's orphan drug reimbursement timelines and approval rates against comparable European jurisdictions; and if she will provide details of any such analysis. [39838/26]